欢迎分享，转载有版权, 快快登录 lingmed.net/reports 获取更多项目信息吧！
在本期的月刊中，灵麦医药和您分享以下信息：
热门抑制剂靶点--MEK全球和中国研发情况分析
2017年11月博谷数据分析团队对全球新药研发行业融资情况的分析
In this month summary, Lingmed reports on:
The hot target of "MEK inhibtor"global and China R&D status analysis
The NovemberFinancial analysis of global bio-pharmaceutical‘s market by Biotechgate data analysis team
PART I 热门抑制剂靶点--MEK全球和中国研发情况分析
本月，灵麦医药独家分享全球和中国的热点靶点MEK抑制剂研发情况分析报告。
This month Lingmed analyst team shares with you the hot target of "MEK inhibtor"global and China R&D status analysis.
表1 中国MEK抑制剂研发现状
Source: Source China, Biotechgate, Lingmed Analysis
欲知更多项目分析报告及行业洞见，请登录www.lingmed.net/reports下载或联系我们info@lingmed.net
PART II 全球新药研发行业融资情况的分析
博谷数据分析团队对全球新药研发行业融资情况的分析
The Financial analysis of global bio-pharmaceuticals market by Biotechgate data analysis team
2017年10月，美国和欧洲生物制药市场融资总额均达到今年最高峰，欧洲达到3.45亿美元，美国达到10.94亿美元。跟去年同期比，欧洲增长了19%，而美国增长了209%。欧美和美国增长如此大的原因主要是三轮融资总额达到了1.5亿美元。而值得注意的是欧洲和美国分别比前一个月减少了7个和5个轮次的融资，但却仍然能保持较高的总额。
今年10月，最大的一轮融资来自于Harmony Biosciences，该公司专注于中枢神经系统疾病药品的开发。
October had the highest aggregate financing amount in biotech therapeutics this year – with both EU (USD 345m) and the US (USD 1094m) seeing record highs. Year-on-year comparisons also yield big discrepancies for both EU (+19%) and US (+209%). The main reason for such a large amount was three rounds having a total of USD 150m+in financing, covering both EU and US. Thus, it is notable that both EU and USA had, respectively, seven and five rounds fewer than in the previous month whilst still recording higher aggregate amounts.
The largest financing round was USD 270m led by Harmony Biosciences, a biopharmaceutical company focusing on CNS disorders.
表2：医药研发企业融资总额及融资总轮数
The graph contains only financing rounds of private and independent biotech therapeutic and diagnostic companies. Financing amounts and number of rounds from previous months may alter as new information on financing rounds is received and/or new tranches to existing financing rounds are added.
图1：医药研发公司各融资规模占总体的比例（美元）
The graph above shows the
proportion of financing for private biotech companies (therapeutics and
diagnostics) by investment series round.The dataset includes only private
Biotech (Therapeutics and Diagnostics) companies from the US and Europe. The
proportion of financing from previous months may alter as new information on
financing rounds is received and/or new tranches to existing financing rounds
are added.
欲知更多2017年11月医药行业融资亮点，请阅读以下报告。
Continue reading below to learn more about industry financing highlights for November 2017.
灵麦医药是以下两家情报数据库在中国的独家合作伙伴：
Biotechgate/博谷 - 全球创新药和器械产品收购和引进数据库
EvaluatePharma/预估医药 - 全球医药研发、销售、市场预估等竞争情报数据库
想要下载完整报告?
请登录 www.lingmed.net/reports
或点击下方“阅读原文”马上下载